BioVascular Inc.
This article was originally published in Start Up
Executive Summary
BioVascular is a beneficiary of Merck KGAA's incubator program. launched to encourage start-up companies to develop Merck's shelved technologies. BioVascular gained rights to saratin, a protein originally isolated from leech saliva. Saratin's ability to reduce platelet adhesion and the complications that can arise from it give it a number of potential applications, but BioVascular's initial focus is on vascular surgery, specifically the prevention of intimal hyperplasia that leads to graft failure.
You may also be interested in...
Start-Up Previews (10/2007)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Cardiovascular Drug Start-Ups," features profiles of AcelleRX Therapeutics, BioVascular, Nile Therapeutics and VIA Pharmaceuticals. Plus these Start-Ups Across Health Care: JenaValve, Moberg Derma, ProtAffin, and Virtual Ports.
Cardiovascular Drug Start-Ups
The cardiovascular drug marketplace has the dubious distinction of being the largest therapeutic category in terms of revenue, unmet need and mortality, while at the same time being the only area experiencing decreasing growth. Revenues will start to plummet starting in 2012 when the world's two largest CV drugs--Lipitor and Plavix--go generic. To help pharmas replace these and other aging drugs in their pipelines, Windhover's Therapeutic Alliances conference presents the "top 10" unpartnered clinical-stage cardiovascular programs.
Cardiovascular Drug Start-Ups
The cardiovascular drug marketplace has the dubious distinction of being the largest therapeutic category in terms of revenue, unmet need and mortality, while at the same time being the only area experiencing decreasing growth. Revenues will start to plummet starting in 2012 when the world's two largest CV drugs--Lipitor and Plavix--go generic. To help pharmas replace these and other aging drugs in their pipelines, Windhover's Therapeutic Alliances conference presents the "top 10" unpartnered clinical-stage cardiovascular programs.